Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -3.3x - -3.7x | -3.5x |
| Selected Fwd P/E Multiple | -4.7x - -5.2x | -5.0x |
| Fair Value | $13.43 - $14.84 | $14.13 |
| Upside | 2.3% - 13.0% | 7.6% |
| Benchmarks | - | Full Ticker |
| BeyondSpring Inc. | - | NasdaqCM:BYSI |
| ADMA Biologics, Inc. | - | NasdaqGM:ADMA |
| Editas Medicine, Inc. | - | NasdaqGS:EDIT |
| Cytokinetics, Incorporated | - | NasdaqGS:CYTK |
| Curis, Inc. | - | NasdaqCM:CRIS |
| Syndax Pharmaceuticals, Inc. | - | NasdaqGS:SNDX |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| BYSI | ADMA | EDIT | CYTK | CRIS | SNDX | |||
| NasdaqCM:BYSI | NasdaqGM:ADMA | NasdaqGS:EDIT | NasdaqGS:CYTK | NasdaqCM:CRIS | NasdaqGS:SNDX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 43.4% | 800.0% | -54.7% | -12.0% | 3.3% | -52.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -6022.5% | -69.0% | -551.0% | -3850.9% | -416.4% | -2854.3% | ||
| Prior Fiscal Year | -2463.3% | -10.9% | -196.1% | -6988.6% | -557.7% | NA | ||
| Latest Fiscal Year | -1200.8% | 46.4% | -733.7% | -3191.1% | -473.0% | -1346.1% | ||
| Latest Twelve Months | -829.9% | 46.4% | -733.7% | -3191.1% | -443.3% | -1346.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -3.2x | 31.7x | 0.6x | -9.2x | -0.8x | -2.3x | ||
| Price / LTM Sales | 32.0x | 11.0x | 3.3x | 279.7x | 2.0x | 47.7x | ||
| LTM P/E Ratio | -3.9x | 23.7x | -0.4x | -8.8x | -0.4x | -3.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -8.8x | -0.4x | 23.7x | |||||
| Historical LTM P/E Ratio | -124.3x | -12.9x | -3.5x | |||||
| Selected P/E Multiple | -3.3x | -3.5x | -3.7x | |||||
| (x) LTM Net Income | (319) | (319) | (319) | |||||
| (=) Equity Value | 1,060 | 1,116 | 1,171 | |||||
| (/) Shares Outstanding | 86.0 | 86.0 | 86.0 | |||||
| Implied Value Range | 12.32 | 12.97 | 13.62 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 12.32 | 12.97 | 13.62 | 13.13 | ||||
| Upside / (Downside) | -6.2% | -1.2% | 3.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BYSI | ADMA | EDIT | CYTK | CRIS | SNDX | |
| Value of Common Equity | 60 | 4,681 | 105 | 5,166 | 20 | 1,130 | |
| (/) Shares Outstanding | 40.3 | 237.6 | 83.0 | 118.4 | 8.5 | 86.0 | |
| Implied Stock Price | 1.49 | 19.70 | 1.27 | 43.63 | 2.39 | 13.13 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.49 | 19.70 | 1.27 | 43.63 | 2.39 | 13.13 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |